| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443143 | European Journal of Cancer | 2014 | 8 Pages |
Abstract
Single-agent bevacizumab treatment in multiresistant EOC appears to be a valuable treatment option with acceptable side-effects. Cell-free DNA showed independent prognostic importance in patients treated with bevacizumab and could be applied as an adjunct for treatment selection.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Karina Dahl Steffensen, Christine Vestergaard Madsen, Rikke Fredslund Andersen, Marianne Waldstrøm, Parvin Adimi, Anders Jakobsen,